Loxapine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Loxapine: From Schizophrenia to Manic Bipolar Affective Disorder
One-Sentence Summary
Loxapine is a first-generation (typical) antipsychotic of the dibenzoxazepine class, originally used for schizophrenia. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, with 20 publications — including data from Phase III RCTs — currently supporting this direction, though no clinical trials are indexed under this specific predicted indication in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (first-generation/typical antipsychotic) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Loxapine is a dibenzoxazepine-class typical antipsychotic with strong D2 dopamine and 5-HT2A serotonin receptor antagonism — a mechanism shared with other antipsychotics used in mania management (e.g., olanzapine, risperidone). No structured MOA field is available from the regulatory source for this candidate, but the mechanistic rationale behind this prediction is well documented in the supporting literature.
Schizophrenia and bipolar mania are both psychotic-spectrum conditions with overlapping dopaminergic dysregulation, which is why antipsychotics developed for one indication are frequently repurposed for the other. In fact, an inhaled formulation of loxapine (Adasuve®) has already been approved in the US and EU for the acute treatment of agitation in both schizophrenia and bipolar I disorder, lending real-world clinical precedent to the TxGNN prediction.
One caveat: the bulk of the supporting evidence concerns loxapine’s use in controlling acute agitation in the context of bipolar disorder, rather than treatment of the manic episode itself. These are overlapping but not fully equivalent clinical targets, and this distinction should be considered when interpreting the evidence level.
Clinical Trial Evidence
Currently no related clinical trials registered under this specific predicted indication.
(Note: several literature entries below reference two completed Phase III RCTs — NCT00628589 and NCT00721955 — but these were not independently captured in the structured clinical trial evidence for this candidate.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29724638 | 2018 | RCT | Eur Neuropsychopharmacol | PLACID trial: inhaled loxapine vs. IM aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder |
| 22226343 | 2012 | RCT (pooled analysis) | Int J Clin Pract | Effect-size analysis from 2 Phase III RCTs of inhaled loxapine for agitation in schizophrenia/bipolar disorder |
| 29163985 | 2017 | RCT (post-hoc) | BJPsych Open | PANSS-EC responder analysis from two Phase III RCTs (NCT00628589, NCT00721955) in schizophrenia and bipolar I agitation |
| 28376877 | 2017 | RCT (protocol) | BMC Psychiatry | Study design of the PLACID trial comparing inhaled loxapine vs. IM aripiprazole for acute agitation |
| 23740380 | 2013 | Review | CNS Drugs | Comprehensive review of inhaled loxapine (Adasuve), approved in the US/EU for acute agitation in bipolar disorder/schizophrenia |
| 27121764 | 2016 | Review | Curr Med Res Opin | Review of inhaled loxapine for urgent treatment of acute agitation in schizophrenia/bipolar disorder |
| 31496709 | 2019 | Review | Neuropsychiatr Dis Treat | Safety, efficacy, and patient acceptability of inhaled loxapine for acute agitation in schizophrenia/bipolar I disorder |
| 38301034 | 2024 | Review | Prim Care Companion CNS Disord | Alternative approaches for managing acute agitation in schizophrenia and bipolar disorder |
| 37581475 | 2023 | Review | Expert Opin Pharmacother | Improving pharmacotherapeutic treatment of agitation associated with bipolar disorder |
| 35913401 | 2022 | Review | Expert Rev Neurother | 50 years of experience with loxapine for rapid non-coercive tranquilization of acute behavioral disturbances |
EU Market Information
No marketing authorizations are on record for this candidate. Market status is currently Not Marketed (0 authorizations), so no license table is available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Literature evidence — including two completed Phase III RCTs and a dedicated head-to-head trial (PLACID) — supports loxapine’s efficacy in acute agitation associated with bipolar I disorder, and an inhaled formulation is already approved for this use elsewhere. However, the evidence centers on agitation control rather than core manic symptom treatment, and critical safety/regulatory data are still missing.
To proceed, the following is needed:
- TFDA/SmPC warnings and contraindications data (currently a blocking data gap, DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Formal linkage of the referenced Phase III trials (NCT00628589, NCT00721955) into structured clinical trial evidence
- Clarification of indication scope: “acute agitation in bipolar disorder” vs. treatment of the manic episode itself
- Confirmation of intended marketing/authorization pathway, given the drug is currently not marketed in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.